Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Sharon Griswold, MD, MPH, Mustfa K. Manzur, MD, MPH, MS, and Wendy Dean, MD
Practice ownership shifts to various employment models have amplified the problem of physician-employees of some US health care companies not knowing about services billed in their names.
AMA J Ethics. 2022;24(11):E1049-1055. doi:
10.1001/amajethics.2022.1049.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Watie White joins Ethics Talk to discuss his article, coauthored with Dr Regina Idoate, Aislinn C. Rookwood, Sophia A. Quintero, Shelby Larson, Dr Arturo Aceves, and Dr Keyonna M. King: “Lead Toxicity and Environmental Health Justice Stories in Black and White Woodcut Portraits.”